By Nana O 
High-grade glioma, a particularly aggressive form of brain cancer affecting both children and adults, presents a formidable therapeutic challenge. Its insidiousness stems from multiple factors: its often deep-seated tumor location within the brain, a high propensity for recurrence even after initial treatment, and the formidable barrier posed by the blood-brain barrier, which severely restricts the passage of many potential drug candidates. For decades, treatment options beyond surgery and radiation have been limited, leaving patients with a grim prognosis and a desperate need for innovative therapies.
In a significant stride toward addressing this critical unmet need, a collaborative research effort involving leading institutions—the University of Michigan, Dana Farber Cancer Institute, and the Medical University of Vienna—has illuminated a promising new avenue for combating high-grade glioma. Their groundbreaking study, recently published in the esteemed journal Cancer Cell, details how a targeted drug, avapritinib, has demonstrated encouraging efficacy in preclinical models and early clinical investigations, specifically in tumors harboring alterations in the PDGFRA gene.
Unlocking a Genetic Key: The Role of PDGFRA in Glioma
The focus on the PDGFRA gene is not arbitrary. This gene plays a crucial role in cell growth and division, and its aberrant activation or mutation is implicated in the development and progression of various cancers, including a significant subset of high-grade gliomas. Researchers identified PDGFRA as one of the most frequently mutated genes in these aggressive brain tumors, making it a compelling target for therapeutic intervention.
"We were excited to see that avapritinib essentially shut off PDGFRA signaling in mouse brain tumors," stated Dr. Carl Koschmann, M.D., a pivotal figure in this research and the ChadTough Defeat DIPG Research Professor and clinical scientific director of the Chad Carr Pediatric Brain Tumor Center at C.S. Mott Children’s Hospital. This observation underscores the direct impact of avapritinib on the molecular pathways driving tumor growth.
The research team embarked on a systematic screening of commercially available drugs known to inhibit PDGFRA. Their meticulous investigation led them to avapritinib, which emerged as the "strongest and most focused inhibitor that targets PDGFRA alterations," according to Dr. Koschmann. This specificity is crucial in cancer therapy, aiming to maximize therapeutic effect while minimizing off-target side effects.
Overcoming the Blood-Brain Barrier: A Critical Hurdle Cleared
A significant obstacle in treating brain cancers is the blood-brain barrier (BBB), a highly selective physiological barrier that protects the central nervous system from circulating toxins and pathogens. While essential for brain health, it also prevents many therapeutic agents from reaching tumor cells effectively. The discovery that avapritinib possesses the ability to cross this formidable barrier was a major breakthrough in the research.
"Along with colleagues from the labs of Mariella Filbin MD, PhD (Dana Farber Cancer Institute) and Johannes Gojo (Medical University of Vienna) who were investigating the effectiveness of PDGFRA inhibitors, Koschmann and his team were excited to see that avapritinib crosses the blood brain barrier, a normally high hurdle for drugs," the original report noted.
Kallen Schwark, a U-M M.D./Ph.D. student and one of the study’s lead authors, elaborated on the significance of this finding: "When we gave mice the drug and showed that it reached the brain, we knew we were onto something." This preclinical validation was instrumental in paving the way for potential human application.
From Bench to Bedside: Early Clinical Investigations
Building on the promising preclinical data, the research team transitioned to early-stage clinical investigations. Recognizing that a formal clinical trial was not yet available, they leveraged an expanded access program established by Blueprint Medicines, the manufacturer of avapritinib. This program allowed for the treatment of a small cohort of patients with high-grade glioma who met specific criteria.
"Across multiple international institutions, we treated the first eight patients with high-grade glioma with avapritinib," Dr. Koschmann reported. The initial results from this expanded access program were encouraging. "The patients tolerated the drug well and in three of the eight patients, we were able to see their tumors shrink."
This preliminary clinical response, while in a small patient group, provided crucial real-world evidence of avapritinib’s potential. The observed tumor shrinkage in a subset of patients offered a glimmer of hope in a disease characterized by limited treatment efficacy.
Laying the Groundwork for Future Trials
The compelling preclinical and early clinical data generated by this collaborative team provided a strong scientific rationale for further clinical development. This work directly contributed to the inclusion of pediatric high-grade glioma in a Phase I pediatric solid tumor trial. This trial has since completed patient accrual, and the analysis of its results is currently underway, representing the next critical step in evaluating avapritinib’s therapeutic potential in a broader patient population.
"We have very few examples of drugs entering brain tumors like this and shutting down key oncogenic pathways. These results support a lot of ongoing efforts to build on the success of avapritinib and other brain penetrant small molecule inhibitors," Dr. Koschmann emphasized. This statement highlights the broader impact of their findings, reinforcing the importance of developing drugs that can effectively penetrate the central nervous system and target cancer-driving molecular pathways.
The Challenge of High-Grade Glioma: A Dire Prognosis
Understanding the context of high-grade glioma is crucial to appreciating the significance of this research. These tumors are notoriously aggressive, often characterized by rapid growth and infiltration into surrounding brain tissue. The prognosis for patients diagnosed with high-grade glioma is typically grim, with a median survival of less than two years, underscoring the urgent need for more effective treatment strategies.
Historically, treatment options have been limited. Surgery aims to remove as much of the tumor as possible, but complete resection is often impossible due to the tumor’s location or infiltrative nature. Radiation therapy is frequently used to target remaining cancer cells. However, chemotherapy has faced significant challenges, primarily due to the BBB. Even when potent chemotherapy drugs are administered, their ability to reach therapeutic concentrations within the brain is often compromised.
The recurrence rate for high-grade gliomas is also exceptionally high. Even after successful initial treatment, cancer cells can persist and regrow, leading to disease progression and further complicating treatment efforts. This cycle of recurrence often leaves patients with few remaining options and a progressively worsening outlook.
A Glimpse into the Timeline of Discovery
The journey from identifying a potential drug target to demonstrating its efficacy in patients is often a lengthy and complex process, typically spanning several years. While a precise timeline for this specific research was not detailed in the initial report, the progression from laboratory-based screening to preclinical studies in animal models, followed by early-stage human trials, represents a standard scientific pathway.
- Initial Hypothesis and Target Identification: Researchers likely began by identifying PDGFRA as a frequently mutated gene in high-grade gliomas, based on existing genomic databases and prior research. This stage involves extensive molecular profiling of tumor samples.
- Drug Screening and Preclinical Validation: The team then systematically screened available drugs that inhibit PDGFRA. Promising candidates like avapritinib would undergo rigorous testing in laboratory settings (cell cultures) and then in animal models (mice) to assess efficacy and, crucially, blood-brain barrier penetration. This phase would have involved multiple experiments to optimize dosing and delivery.
- Expanded Access Program: Based on the compelling preclinical data, the researchers sought regulatory approval and manufacturer collaboration to initiate an expanded access program, allowing a limited number of patients to receive the drug outside of a formal clinical trial. This phase would have involved careful patient selection and close monitoring.
- Clinical Trial Initiation: The positive, albeit preliminary, results from the expanded access program provided the evidence needed to advocate for and design a formal Phase I clinical trial. This trial aims to further evaluate safety, determine optimal dosage, and gather more robust efficacy data in a controlled setting.
- Analysis and Future Development: The completion of patient accrual in the Phase I trial marks a significant milestone. The ongoing analysis of this data will determine the next steps in avapritinib’s development for high-grade glioma, potentially leading to larger Phase II and III trials.
Broader Implications and the Future of Glioma Treatment
The success of avapritinib in crossing the blood-brain barrier and demonstrating tumor shrinkage in some patients carries profound implications for the future of high-grade glioma treatment. It validates the strategy of targeting specific genetic alterations within brain tumors, a personalized medicine approach that is gaining traction across oncology.
"We know a single drug is not going to be enough for this disease," Dr. Koschmann rightly stated, acknowledging the complexity of high-grade glioma. This sentiment reflects the scientific consensus that a multi-pronged approach is likely necessary to achieve durable remissions and improve patient outcomes.
The research team is already looking ahead, exploring combination therapies. "The way to make true progress will be combining many different types of modalities, like combining drugs that are target pathways activated by the first drug. We already have a follow-up story on targeting avapritinib with MAP kinase inhibitors that we are just as excited about," Dr. Koschmann revealed. This forward-thinking strategy of targeting complementary pathways is a testament to the evolving landscape of cancer therapy, moving beyond single-agent treatments to more sophisticated combination regimens.
The implications extend beyond high-grade glioma. The success in developing and testing a brain-penetrant drug for this challenging cancer could pave the way for similar approaches to other neurological cancers or even neurological diseases where drug delivery to the brain is a significant hurdle. The development of avapritinib as a tool against high-grade glioma, while still in its early stages, represents a significant step forward, offering a beacon of hope to patients and families affected by this devastating disease. The scientific community will be keenly awaiting the full results of the ongoing clinical trial and the subsequent research into combination therapies.
